Innate lymphoid cell

Generation Bio Reports Business Highlights and Third Quarter 2023 Financial Results

Retrieved on: 
星期四, 十一月 9, 2023
Cytokine, DNA, Spleen, D, Haemophilia, Gene, Therapeutic index, Liver, Tissue, Mouse, Cell, Research, ESGCT, G&A, Messenger, LNP, Innate lymphoid cell, NHP, Moderna, R, Congress, RNA, Vaccine

CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and third quarter 2023 financial results.

Key Points: 
  • (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and third quarter 2023 financial results.
  • “The recent advances in our immune-quiet DNA (iqDNA) and cell-targeted lipid nanoparticle (ctLNP) platforms represent two breakthroughs in the field of genetic medicine,” said Geoff McDonough, chief executive officer of Generation Bio.
  • R&D Expenses: Research and development (R&D) expenses were $21.9 million for the quarter ended September 30, 2023, compared to $21.2 million for the quarter ended September 30, 2022.
  • G&A Expenses: General and administrative (G&A) expenses were $11.6 million for the quarter ended September 30, 2023, compared to $11.5 million for the quarter ended September 30, 2022.

SinoMab's IND Application of SM17 has once again Received Approval from NAMP

Retrieved on: 
星期二, 九月 12, 2023
Asthma, T helper cell, Therapy, Prevalence, Infection, Quality of life, Atopic dermatitis, Research, Innate lymphoid cell, Investigational New Drug, Patient, FIC, ILC2, National Medical Products Administration, Cytokine, Mortality, AD, IND, NMPA, Autoimmunity, Skin, Conditional sentence, Pharmaceutical industry

Current approved therapies for AD, including biologics, can significantly improve eczema area and severity index and patient's quality of life.

Key Points: 
  • Current approved therapies for AD, including biologics, can significantly improve eczema area and severity index and patient's quality of life.
  • The Company actively promoted the indication research of SM17, laying a foundation for subsequent proof of concept and commercialization.
  • The IND application of SM17 for AD has been approved by the NMPA, which fully reflects the recognition of the differentiated advantages of SM17 in the field of AD and has a bright future.
  • Currently, SM17 has obtained IND approvals from the NMPA for the treatment of asthma and AD, while our Phase I study for SM17 conducted in the US is near completion.

SinoMab Announces that IND Application of SM17 for the Treatment of Asthma was Approved by NAMP

Retrieved on: 
星期一, 八月 14, 2023
Idiopathic disease, Asthma, Idiopathic pulmonary fibrosis, Therapy, Lincoln Hospital (Bronx), Clinical trial, Quality of life, Atopic dermatitis, Research, Innate lymphoid cell, Frost, Investigational New Drug, Patient, Risk, Health, FIC, Disease, ILC2, National Medical Products Administration, FIH, Mortality, Cytokine, FDA, IPF, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, NMPA, Social Problems, Food, T helper cell, Safety, Pharmaceutical industry, Vaccine

IL-25 is a critical cytokine classified as "alarmin", which has shown to be implicated in the pathogenesis of multiple airway viral responses and allergic diseases, such as asthma.

Key Points: 
  • IL-25 is a critical cytokine classified as "alarmin", which has shown to be implicated in the pathogenesis of multiple airway viral responses and allergic diseases, such as asthma.
  • Meanwhile, the Company is also advancing the Phase I clinical study of SM17 in the U.S. at full speed.
  • The potential first-in-target antibody of SM17 has demonstrated the potential efficacy for multiple indications, including asthma and IPF (Idiopathic Pulmonary Fibrosis).
  • Compared with other currently approved therapeutic antibody drugs targeting ILC2s downstream pathway, SM17 has a differentiated advantage at the source.

SinoMab Announces IND Application of SM17 for the Treatment of Asthma was Accepted by NMPA CDE

Retrieved on: 
星期一, 五月 22, 2023
Drug development, T helper cell, Therapy, Lincoln Hospital (Bronx), Clinical trial, Quality of life, Atopic dermatitis, Research, Innate lymphoid cell, Trial of the century, Frost, Investigational New Drug, Patient, Risk, Health, Allergy, ILC2, National Medical Products Administration, FIH, Center for Drug Evaluation and Research, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Idiopathic pulmonary fibrosis, Food, NMPA, Safety, Pharmaceutical industry, Vaccine, Asthma

The present IND submission, once granted, will enable the Company to conduct comprehensive clinical development program in China which leads to indication for treatment of asthma.

Key Points: 
  • The present IND submission, once granted, will enable the Company to conduct comprehensive clinical development program in China which leads to indication for treatment of asthma.
  • Current approved therapies for severe asthma, including biologics, can reduce asthma annual exacerbations to a certain extent.
  • The Company believes SM17 may have great potential to satisfy unmet medical needs in asthma treatment.
  • It is expected that this new treatment option will benefit more Chinese patients in the future and bring a promising treatment for severe asthma patients.

SinoMab Annouces IND Application of SM17 for the Treatment of Asthma was Accepted by NMPA CDE

Retrieved on: 
星期一, 五月 22, 2023
Drug development, T helper cell, Therapy, Lincoln Hospital (Bronx), Clinical trial, Quality of life, Atopic dermatitis, Research, Innate lymphoid cell, Trial of the century, Frost, Investigational New Drug, Patient, Risk, Health, Allergy, ILC2, National Medical Products Administration, FIH, Center for Drug Evaluation and Research, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Idiopathic pulmonary fibrosis, Food, NMPA, Safety, Pharmaceutical industry, Vaccine, Asthma

The present IND submission, once granted, will enable the Company to conduct comprehensive clinical development program in China which leads to indication for treatment of asthma.

Key Points: 
  • The present IND submission, once granted, will enable the Company to conduct comprehensive clinical development program in China which leads to indication for treatment of asthma.
  • Current approved therapies for severe asthma, including biologics, can reduce asthma annual exacerbations to a certain extent.
  • The Company believes SM17 may have great potential to satisfy unmet medical needs in asthma treatment.
  • It is expected that this new treatment option will benefit more Chinese patients in the future and bring a promising treatment for severe asthma patients.

First Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Retrieved on: 
星期二, 七月 11, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, CD16, FACP, Cancer, Pharmacokinetics, NK, Cross, Euronext Paris, IPH, MD, Patient, IPHA, Master of Science, RRMM, Safety, News, BCMA, Pharmaceutical industry, Vaccine, Innate lymphoid cell, NCR1, Sanofi

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the first patient was dosed in a Sanofi-sponsored Phase 1/2 clinical trial ( NCT05839626 ), evaluating SAR’514 / IPH6401 in relapsed/refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)1.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the first patient was dosed in a Sanofi-sponsored Phase 1/2 clinical trial ( NCT05839626 ), evaluating SAR’514 / IPH6401 in relapsed/refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)1.
  • SAR’514 is a trifunctional anti-BCMA NKp46xCD16 NK cell engager, using Sanofi’s proprietary CROSSODILE® multi-functional platform, which comprises the Cross-Over-Dual-Variable-Domain (CODV) format.
  • It induces a dual targeting of the NK activating receptors, NKp46 and CD16, for an optimized NK cell activation, based on Innate’s ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform.
  • Our first patient dosed with SAR’514 / IPH6401 is indeed welcome news.

Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers

Retrieved on: 
星期三, 一月 25, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Hart–Scott–Rodino Antitrust Improvements Act, Sanofi, IPHA, HSR, IPH, Natural killer T cell, NK, Euronext Paris, Pharmaceutical industry, Vaccine, Innate lymphoid cell

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 with respect to the previously announced expansion of its collaboration with Sanofi.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 with respect to the previously announced expansion of its collaboration with Sanofi.
  • As announced on December 19, 2022, Sanofi is licensing a Natural Killer (NK) cell engager program targeting B7H3 from Innate’s ANKET® (Antibody-based NK Cell Engager Therapeutics) platform.
  • Sanofi will also have the option to add up to two additional ANKET® targets.
  • Upon candidate selection, Sanofi will be responsible for all development, manufacturing and commercialization.

SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SM17 in the U.S.

Retrieved on: 
星期三, 六月 15, 2022
Organic, Industry, T helper cell, FDA, Food and Drug Administration, Therapy, Health, FIC, Safety, State, The Company, NHL, RA, CD22, SM03, Pemphigus vulgaris, Company, Coronavirus Scientific Advisory Board (Turkey), Asthma, Pharmacokinetics, Innate lymphoid cell, Research, B-cell lymphoma, Disease, Investigational New Drug, Rheumatoid arthritis, Mab, FRS, Molecular biology, MRC Laboratory of Molecular Biology, IND, Quality of life, SAD, Lupus, LifeArc, Single, Thirteenth, SLE, Food, Patient, Francis Crick Institute, United Kingdom, PV, MAD, Twelfth, LMB, The Group, Risk, Pharmaceutical industry, ILC2

SM17 is currently under development by SinoMab, and was engineered by LifeArc (a leading medical research charity based in the United Kingdom).

Key Points: 
  • SM17 is currently under development by SinoMab, and was engineered by LifeArc (a leading medical research charity based in the United Kingdom).
  • Despite the pandemic, SinoMab have soon initiated the first-in-human dose in the Phase I clinical trial.
  • After evaluating and choosing the lead candidate, it was licensed to SinoMab to take forward into clinical development and towards patients.
  • Following our flagship product, SM03 and key product, SN1011, we now have another key asset entering the clinical trial stage.

I-Mab to Present Preclinical Data of TJ210 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
星期二, 十月 27, 2020
Branches of biology, Cell biology, Phagocytes, Immune system, Myeloid-derived suppressor cell, Tumor microenvironment, Cancer immunotherapy, C5a receptor, Neutrophil, Macrophage, Complement component 5a, Innate lymphoid cell

TJ210/MOR210 is a novel human antibody directed against C5aR derived from MorphoSys's HuCAL Platinum technology.

Key Points: 
  • TJ210/MOR210 is a novel human antibody directed against C5aR derived from MorphoSys's HuCAL Platinum technology.
  • C5aR, the receptor of the complement factor C5a, is investigated as a potential new drug target in the field of immuno-oncology and autoimmune diseases.
  • Tumors have been shown to produce high amounts of C5a, which, by recruiting and activating myeloid-derived suppressor cells (MDSCs), M2 macrophages and neutrophils, is assumed to contribute to an immune-suppressive pro-tumorigenic microenvironment.
  • TJ210/MOR210 is intended to block the interaction between C5a and its receptor, thereby potentially neutralizing the immune suppressive function and enabling immune cells to attack the tumor.

Simcha Therapeutics Launches to Engineer Therapeutic Cytokines to Unlock the Full Potential of the Immune System

Retrieved on: 
星期三, 六月 24, 2020
Oncology, Health, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Medical specialties, Immunology, Medicine, Cytokine, Immune system, T helper cell, Innate lymphoid cell

Simcha was founded to overcome those obstacles by using directed evolution to engineer a new generation of cytokines with improved properties relative to those of their native variants.

Key Points: 
  • Simcha was founded to overcome those obstacles by using directed evolution to engineer a new generation of cytokines with improved properties relative to those of their native variants.
  • Cytokines represent a compelling therapeutic class because they tap into pathways that are hard-wired into immune cells.
  • Simchas lead asset, ST-067, activates the IL-18 receptor, triggering potent inflammatory signaling in antitumor immune cells of both the adaptive and innate branches of the immune system.
  • Simcha Therapeutics uses directed evolution to engineer novel cytokines designed to unlock the precision and power of the immune system.